Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Baseline Characteristics in PRIORITY Study: Proteomics and Mineralocorticoid Receptor Antagonism for Prevention of Diabetic Nephropathy in Type 2 Diabetes

Research output: Contribution to conferenceConference abstract for conferenceResearch

  1. ASN Kidney Week 2017

    Activity: Participating in or organising an eventOrganisation of and participation in conference

  1. Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Metabolites of the mitochondrial energy production are associated with future cardiovascular morbidity and mortality in type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations
Background In PRIORITY (Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria) the aim is to test if the urinary proteomics based classifier CKD273 can predict microalbuminuria prospectively, and to test whether mineralocorticoid receptor antagonism (MRA) delays progression to microalbuminuria. Methods Prospective, randomized, double-blind, placebo-controlled multicentre clinical trial and observational study in normoalbuminuric type 2 diabetic patients. Patients are stratified into high- or low risk groups based on CKD273. Patients in the high risk group are assigned to spironolactone 25 mg once daily or placebo, the low-risk group is followed on standard care. Patients are followed for up to 4.5 years. Primary endpoint is development of microalbuminuria. Results From 15 sites we have included 1811 patients. The high- and low-risk populations differ in terms of gender, age, diabetes duration, UACR and eGFR (table). Univariate regression analyses of CKD273 vs each baseline variable demonstrated weak associations (R2 of 0.03, p <0.0001) for the strongest correlations with UACR and eGFR. In a logistic regression model predicting CKD273 risk strata, including all baseline variables, eGFR and UACR remain statistically significant (p < 0.0003) with an AUC of 0.70 (95 % CI: 0.65, 0.74). Conclusion Classical risk factors for diabetic kidney disease differ only slightly, and overlap to a great extent, between high and low risk patients based on the urinary proteomics based risk classifier CKD273 in type 2 diabetes, suggesting it provides additional information to the measures already available in the clinic. The potential added value will be tested in this prospective study.
Original languageEnglish
Publication date2 Nov 2017
Number of pages1
Publication statusPublished - 2 Nov 2017
EventASN Kidney Week 2017 - Ernest N. Morial Convention Center, New Orleans, United States
Duration: 31 Oct 20175 Nov 2017
https://www.asn-online.org/kidneyweek/

Conference

ConferenceASN Kidney Week 2017
LocationErnest N. Morial Convention Center
CountryUnited States
CityNew Orleans
Period31/10/201705/11/2017
Internet address

Event

ASN Kidney Week 2017

31/10/201705/11/2017

New Orleans, United States

Event: Conference

ID: 52001302